Citadel Advisors
BIO icon

Citadel Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Citadel Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$910K Buy
3,100
+1,500
+94% +$425K ﹤0.01% 8427
2026
Q1 		$446K Sell
1,600
-500
-24% -$144K ﹤0.01% 9569
2025
Q4 		$636K Sell
2,100
-900
-30% -$281K ﹤0.01% 8436
2025
Q3 		$841K Sell
3,000
-2,300
-43% -$626K ﹤0.01% 7923
2025
Q2 		$1.28M Sell
5,300
-5,300
-50% -$1.25M ﹤0.01% 6566
2025
Q1 		$2.58M Sell
10,600
-400
-4% -$120K ﹤0.01% 5041
2024
Q4 		$3.61M Buy
11,000
+2,600
+31% +$883K ﹤0.01% 4516
2024
Q3 		$2.81M Buy
8,400
+100
+1% +$31.8K ﹤0.01% 4907
2024
Q2 		$2.27M Sell
8,300
-4,400
-35% -$1.28M ﹤0.01% 5078
2024
Q1 		$4.39M Sell
12,700
-14,600
-53% -$4.8M ﹤0.01% 4139
2023
Q4 		$8.81M Buy
27,300
+2,900
+12% +$909K ﹤0.01% 3016
2023
Q3 		$8.75M Sell
24,400
-5,300
-18% -$2.04M ﹤0.01% 2860
2023
Q2 		$11.3M Buy
29,700
+9,600
+48% +$3.91M ﹤0.01% 2524
2023
Q1 		$9.63M Sell
20,100
-32,400
-62% -$15.2M ﹤0.01% 2862
2022
Q4 		$22.1M Sell
52,500
-34,900
-40% -$14.1M 0.01% 1864
2022
Q3 		$36.5M Buy
87,400
+39,600
+83% +$19.7M 0.01% 1314
2022
Q2 		$23.7M Buy
47,800
+4,500
+10% +$2.34M 0.01% 1671
2022
Q1 		$24.4M Buy
43,300
+31,300
+261% +$18.9M 0.01% 1761
2021
Q4 		$9.07M Sell
12,000
-22,100
-65% -$16.5M ﹤0.01% 3238
2021
Q3 		$25.4M Buy
34,100
+18,100
+113% +$13.6M 0.01% 1726
2021
Q2 		$10.3M Buy
16,000
+2,400
+18% +$1.46M ﹤0.01% 3019
2021
Q1 		$7.77M Buy
+13,600
New +$8.05M ﹤0.01% 3392

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Citadel Advisors's BIO Position: Q2 2026 in Review

Citadel Advisors reduced its Bio-Rad Laboratories Class A (BIO) stake by 59% in Q2 2026, selling an estimated $24.9M and leaving 60,819 shares worth $17.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2737.

Citadel Advisors first reported a position in BIO in Q2 2013 and has held it in 51 quarters since. The position peaked at $76.5M in Q1 2022. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Citadel Advisors held 60,819 shares of Bio-Rad Laboratories Class A worth $17.9M as of Q2 2026.
  • Citadel Advisors sold 87,850 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $24.9M.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2737 holding.
  • Citadel Advisors first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and has held it in 51 quarters since.
  • Citadel Advisors's Bio-Rad Laboratories Class A position peaked at $76.5M in Q1 2022.
  • 398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.